Results 151 to 160 of about 5,257 (166)

Tolvaptan: A New Therapeutic Agent

Reviews on Recent Clinical Trials, 2011
Tolvaptan is a new agent in the treatment of normovolemic and hypervolemic hyponatremia. It is a V(2) receptor antagonist inducing free water diuresis. It has been recently approved in USA and Europe for the treatment of hyponatremia associated with SIADH, cirrhosis as well as heart failure, while in hypovolemic hyponatremia its use is contraindicated.
Polichronis Alivanis, Georgios Aperis
openaire   +3 more sources

Nonclinical Safety Profile of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
In the present study, the nonclinical safety profile of tolvaptan was evaluated.A series of safety pharmacology and toxicology studies were performed in vitro and in mice, rats, dogs, rabbits and guinea pigs.In safety pharmacological studies, tolvaptan had no adverse effects on the central nervous, somatic nervous, autonomic nervous, smooth muscle ...
Katsumi Morishita, Toshiyuki Shiragiku, Hajime Morimoto, Tadashi Senba, Takumi Awogi, Tohru Uesugi, S Fujita, Atsushi Ozaki, Norio Ito, Masaya Miyatake, Naoto Nakagiri, Nobuya Ishiharada, Masanao Umezato, Akihide Oi, Hironobu Ishiyama, Eiji Hosoki   +15 more
openaire   +3 more sources

Tolvaptan in Hyponatremia – A Pharmacologic approach

Research Journal of Pharmacy and Technology, 2021
Tolvaptan is the first orally active vasopressin receptor 2 antagonist approved by FDA in 2009 for the treatment of clinically significant hypervolemic and euvolemic hyponatremia associated with heart failure, syndrome of inappropriate antidiuretic hormone secretion, liver cirrhosis.
Lakshmi. R, Anna Paul
openaire   +2 more sources

Tolvaptan efficacy and drug-drug interactions

Minerva Endocrinologica, 2020
Discussion of the presence of drug-drug interactions that may affect the efficacy of tolvaptan in hyponatremic patients affected by ...
Giampaolo Corti, Gregorio Basile, Gabriele Parenti, Filippo Bartalesi, Alessandro Peri, Alessandro Bartoloni, Matteo Piccica, Alberto Farese, Lisa Buci   +8 more
openaire   +4 more sources

Tolvaptan bei Zystennieren?

DMW - Deutsche Medizinische Wochenschrift, 2013
Vasopressin-V 2 -Rezeptor-Antagonisten reduzierten in fruheren Studien die Zystenlast und hatten protektive Effekte auf die Nierenfunktion. Torres et al. fuhrten nun eine multizentrische, randomisierte, kontrollierte, doppelblinde Phase-III-Studie zur Wirksamkeit und Sicherheit von Tolvaptan durch.
openaire   +2 more sources

[From hyponatremia to tolvaptan].

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2014
Hyponatremia is the electrolytic disorder that is observed most frequently in hospitalized patients. Itinfluences prognosis in the short, mid and long term. Although many cases are asymptomatic, hyponatremia can cause severe neurological symptoms, depending on the amount of serum sodium reduction and on the rapidity with which it occurs.
CERNARO, VALERIA, SANTORO, Domenico, LACQUANITI, ANTONIO, MONTALTO, Gaetano, BUEMI, Michele   +4 more
openaire   +2 more sources

Cost effectiveness of tolvaptan

BMJ, 2011
Amin and Meeran refer to the relative expense of tolvaptan, one of the new vasopressin 2 receptor antagonists.1 They suggest that it has little benefit over existing treatments but fail to mention …
openaire   +2 more sources

Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact

American Journal of Health-System Pharmacy, 2013
The bioavailability of a crushed tolvaptan tablet suspended in water and administered by nasogastric (NG) tube was compared to the bioavailability from the tablet administered whole.In a randomized crossover study, 28 healthy adults received a single 15-mg dose of tolvaptan on two occasions (one dose given as an intact tablet swallowed whole and the ...
Kim L. R. Brouwer, J. Heyward Hull, Jasmine A. Talameh, Jill Henry, Elizabeth B. McNeely, B. Simmons, J. Herbert Patterson, Kirkwood F. Adams   +7 more
openaire   +3 more sources

Tolvaptan for Volume Management in Heart Failure

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
Volume management in acute decompensated and chronic heart failure (HF) remains a significant challenge. Although progress has been made in the development of mortality‐reducing neurohormonal regimens in the reduced ejection fraction population, no clinical trial has yet demonstrated anything more than symptomatic relief or biomarker reduction with ...
Erik G. Gunderson, Matthew P. Lillyblad, Michelle Fine, Orly Vardeny, Theodore J. Berei   +4 more
openaire   +3 more sources

Synthesis of the major metabolites of Tolvaptan

Chinese Chemical Letters, 2012
Tolvaptan is a nonpeptide arginine vasopressin (AVP) V2-receptor antagonist and used in the treatment of heart failure, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion or other high-volume capacity of hyponatremia. The metabolites of tolvaptan are mainly produced by CYP3A4, including two major compounds named DM-4103 and DM-4107 ...
Yong Wu, Fan Lei, Jianbo Wu, Xiao Long Li, Li Hai, Wei Li Wan   +5 more
openaire   +2 more sources